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Background: the objective of this study is to investigate the detection rate of undiagnosed atrial fibrillation (AF)
with short intermittent ECG recordings during four weeks among out-of-hospital patients, having at least one
additional risk factor (CHADS2) for stroke.
Method: Design: Cross-sectional study. Setting: Eight family practice centres and two hospital-based out-patient
clinics in Sweden. Subjects: 989 out-of-hospital patients, without known AF, having one or more risk factors
associated with stroke (CHADS2). Interventions: All individuals were asked to perform 10-second handheld ECG
recordings during 28 days, twice daily and when having palpitations. Main outcome measures: Episodes of AF on
handheld ECG recordings were defined as irregular supraventricular extrasystoles in series with a duration of
10 seconds.
Results: 928 patients completed registration. AF was found in 35 of 928 patients; 3.8% (95% confidence interval [CI]
2.7–5.2). These 35 patients had a mean age of 70.7 years (SD ± 7.7; range 53–85) and a median CHADS2 of 2 (range
1–4).
Conclusions: Intermittent handheld ECG recording over a four week period had a detection rate of 3.8% newly
diagnosed AF, in a population of 928 out-of-hospital patients having at least one additional risk factor for stroke.
Intermittent handheld ECG registration is a feasible method to detect AF in patients with an increased risk of stroke
in whom oral anticoagulation (OAC) treatment is indicated.
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Atrial fibrillation/flutter (AF) is the most common type
of arrhythmia occurring in 1–2% of the adult population.
With increasing age the prevalence of AF increases.
Approximately 5% of the population over 65 years and
10% of the population over 80 years has AF [1-5]. A re-
cent Swedish study shows an even higher overall preva-
lence of 2.5% and a prevalence of 13.8% in those over
80 years [6].
Occurrence of AF constitutes in itself an independ-
ent risk factor for stroke [7], and with other concur-
rent risk factors, congestive heart failure, hypertension,* Correspondence: tijn.hendrikx@fammed.umu.se
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reproduction in any medium, provided the orage ≥75 years, diabetes and earlier stroke (CHADS2
score), this risk is additionally increased [8,9]. In AF
patients with a CHADS2 score of ≥ 1, treatment with
oral anticoagulation (OAC) should be considered. In
AF patients with a CHADS2 score of ≥ 2 chronic OAC
is recommended to prevent stroke [9].
AF was found in 28.7% (of 152 746) Swedish stroke
patients at admission to hospital 2001–2008 [10]. Since
AF is often asymptomatic it may remain undiagnosed
for a long time and many of these patients will not re-
ceive OAC before suffering a stroke [11]. It has been
estimated that only one in ten paroxysms of AF are
symptomatic [12,13]. Several studies have shown that
patients with paroxysmal AF have the same stroke inci-
dence as patients with permanent AF [14-16].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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without known AF have episodes of asymptomatic AF
beyond that detected by physical examination and initial
ECG during hospital admission for acute ischemic stroke
[17-19]. A recent study shows that intermittent hand-
held ECG recording after carrying out Holter ECG sub-
stantially improves the detection of asymptomatic atrial
fibrillation (AF) in post-stroke patients [20].
AF in the general population is traditionally detected
with pulse registration/palpation, 12-lead resting ECG
[21-23] or 24-hour Holter/Event recorder ECG [24],
but these methods have a relatively low sensitivity for
detection of asymptomatic AF. As a result the preva-
lence of undiagnosed AF in the general population is
not well known.
The objective of this study is to estimate the detection
rate of undiagnosed AF among out-of-hospital patients,
having at least one additional risk factor (CHADS2) for
stroke, using intermittent 10-second ECG recording dur-
ing 28 days with a handheld device.
Methods
Design, study population and setting
In this cross-sectional study patients from eight family
practice centres and two hospital-based out-patient
clinics in Sweden, having one or more risk factors asso-
ciated with stroke (CHADS2 score), without known AF,
were identified from physicians’ and nurses’ surgery lists
and included consecutively.
Inclusion period
The inclusion period extended from May 2007 until June
2011.
Intervention
Inclusion criteria: one or more risk factors associated
with stroke (CHADS2 score). Exclusion criteria: known
AF, impaired cognitive function or other functional im-
pairments that prevent the use of the handheld device.
When AF was detected during the study an additional
review of the patient’s medical record and existing ECGs
five years back in time was done to reveal unreported
previous episodes of AF. Patients with such episodes of
AF were excluded.
After giving informed consent patients were instructed
to perform a 10 second handheld ECG (Zenicor EKG®).
When AF was detected at the first registration, patients
were referred for treatment without further registrations.
If no AF was seen at the first registration, patients were
asked to perform a similar 10-second handheld ECG
(Zenicor EKG®) registration during 28 days, twice daily
(morning and evening) and when having palpitations.
After every registration the recording was transmitted by
the patient via phone to an internet-based centraldatabase. ECG registrations were evaluated at least once
a week by a study nurse and when in doubt the ECG was
additionally checked by a single physician, having the pos-
sibility to contact a cardiologist in uncertain cases. Pa-
tients with detected AF were referred for treatment in
accordance with national guidelines to the patients’ regu-
lar family physician or to a cardiologist. Patients with less
than 20 registrations were excluded. (For additional infor-
mation see Figure 1: study flowchart).
Outcome measures
We defined episodes of AF on handheld ECG recordings
as irregular supraventricular extrasystoles in series with
a duration of 10 seconds. Ambiguous recordings, show-
ing repetitive irregular supraventricular extrasystoles
(SVES) less than 10 seconds, were referred for an add-
itional 24-hour Holter ECG. AF on Holter was defined
by at least 10 seconds showing irregular rhythm without
sinus P-waves.
Paroxysmal AF was defined as self-terminating, usually
within seven days. Persistent AF was defined as an AF
episode that either lasts longer than 7 days (but less than
a year) or requires termination by cardioversion, either
with drugs or by direct current cardioversion (DCC) [9].
The device
ECG recordings were performed using a handheld de-
vice, Zenicor EKG®, which via both thumbs registers a
bipolar extremity lead I ECG during 10 seconds. After
each registration the recording was transmitted by the
patient via phone to a web-based central database. The
ability to give the correct diagnosis of AF compared to
12-lead ECG has shown a sensitivity of 96% and a speci-
ficity of 92% [25]. A detailed technical description of the
device, and its performance is published elsewhere [25].
(An example of AF as recorded with the handheld ECG
device is given in Figure 2. Figure 3 shows a photo of
the handheld ECG device).
Statistics
The statistics of this study were mainly descriptive. Con-
tinuous variables were presented with mean, standard
deviation (SD) and range (minimum and maximum)
whereas categorical variables were presented with count
and percentage and, where appropriate, a 95% confi-
dence interval. Pearson Chi Square test was used to test
for differences in AF detection rate for gender, age cat-
egories and CHADS2 risk factors. To evaluate possible
differences in the number of registrations, age and total
CHADS2 risk score between individuals with and with-
out detected AF, the Mann–Whitney U test was used.
SPSS Statistics 19.0 (IBM Corporation, Route 100 Somer,
NY 10589) was used for all calculations. The level of sig-
nificance was set at 0.05, two-sided. The sample size was
Figure 1 Study flowchart.
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approximately 1000 patients this would yield a 95%
confidence interval of ± 1%, which was deemed narrow
enough to answer the objective.Ethical considerations
The study was approved by the Regional Ethics Commit-
tee (Dnr 07-051 M). All participating patients gave writ-
ten informed consent.Figure 2 Example of registration of AF with handheld ECG.Results
Demographics
A total of 989 patients, 491 men and 498 women, en-
tered the study. Forty-nine patients with fewer than 20
recordings did not complete registration because of tech-
nical or medical problems. Twelve patients were excluded
due to initial inappropriate inclusion. Clinical characteris-
tics of the remaining 928 patients are displayed in Table 1.
The mean number of registrations per patients, with re-
spect to a recommended number of 56 registrations, was
Figure 3 Photo of the handheld ECG device.
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was no statistical correlation between AF detection
and the number of registrations (Mann–Whitney U
test, P = 0.442).
Detection of AF and AF characteristics
Analysis of our data showed newly diagnosed AF in 35
of these 928 patients (3.8% (95% confidence interval [CI]
2.7–5.2)). Characteristics of AF patients are displayed in
Table 1 and a study flowchart (Figure 1). Twenty-eight
of these AF patients were detected with handheld ECG
alone; nine patients at the time of their first handheld
ECG recording, nineteen patients after 28 days of inter-
mittent handheld ECG recording. Follow-up showed
that of nine patients discovered at day one six had per-
sistent AF and three paroxysmal AF. One additional
patient who continued with registrations after day 28
had one AF episode at day 38. As this was not detected
within 28 days he was not counted as newly diagnosed
AF within the study framework. Seven patients showing
episodes of repetitive irregular supraventricular extra-
systoles (SVES) less than 10 seconds on handheld regis-
trations were diagnosed with AF after an additional
24-hour Holter ECG.
Eighty percent of patients with detected AF were
aged ≥ 65 years. The AF detection rate for patients
< 65 years was 2.9% and for patients ≥ 65 years 4.1%(Pearson Chi Square test, P = 0.404). The patients in this
study had in general low CHADS2 scores with a median
of 2 (range 1–5). Slightly higher detection rates for AF
could be seen among those with CHADS2 ≥ 2 compared
to those with a score of 1, but no significant differences
were seen (Pearson Chi Square test, P = 0.351). More
male than female patients were discovered (4.6% and
3.0% respectively), but this difference was not significant
(Pearson Chi Square test, P = 0.218).
In AF patients AF was recorded in 33.7% of registrations
on average (SD ± 41.1 and range 1.3%–100%). Characteris-
tics of AF registrations are displayed in Table 2.
There was no difference regarding whether AF oc-
curred in the morning or the evening. Only 12.4% of AF
registrations were related to symptoms. On average AF
was diagnosed after 7.3 days (SD ± 7.6; range 1–28).
(Time to detection is illustrated in Figure 4). More than
eighty percent of AF patients discovered with handheld
ECG were found within 14 days. Six patients had a per-
sistent AF. Four patients had atrial flutter. In case of typ-
ical p-wave morphology, as in atrial flutter, diagnosis
was confirmed with 12-lead ECG or Holter ECG.
Additional holter ECG investigation
Thirty additional Holter investigations were done. Twenty-
four Holter recordings were made because of suspected
AF on handheld ECG and resulted in seven more AF diag-
noses. Four of these patients had episodes of more than
30 seconds on Holter; three had episodes of more than
10 seconds but less than 30 seconds. Six Holter investiga-
tions were done because of suspected brady-arrhythmias.
Five patients received a pacemaker because of diagnosis of
AV block II-III or sinus arrest. All five patients had a
CHADS2 of 2, mainly hypertension and age ≥ 75. Three of
them had ischemic heart disease. Their average age was
74.4 years with a range of 58–85.
Discussion
Opportunistic screening in an out-of-hospital population
with at least one risk factor for stroke (CHADS2)
resulted in detection of 3.8% previously unknown AF,
higher than in previous studies of out-of-hospital popu-
lations [21-23]. These results, if replicated in other stud-
ies, show the possibilities for the use of intermittent
ECG registration as a screening instrument for detection
of AF. A detection rate of 3.8% newly diagnosed AF is
high, especially when considering that the study popula-
tion was relatively young and healthy with few CHADS2
risk factors. AF patients were on average slightly older
and had slightly higher CHADS2 risk factors than non-
AF patients, but no statistically significant clinical differ-
ences were seen.
A survey of previously published studies did not reveal
data comparing the efficiency of intermittent ECG
Table 2 AF characteristics of newly diagnosed AF patients
Paroxysmal AF, n (%) 29 (82.9%)
Persistent AF, n (%) 6 (17.1%)
Atrial fibrillation, n (%) 31 (88.6%)
Atrial flutter, n (%) 4 (11.4%)
Time to AF detection with
Handheld ECG (n = 28)
Day 1 9 (32.1%)
Day 2–14, n (%) 14 (50.0%)





AF registration (% of total
registration time)
33.7% ± 41.1 1.3%–100%
AF at morning registration (% of
AF registrations)
47.7% ± 34.5 0%–100%
Symptoms registered at AF
episode (% of AF registrations)
12.4% ± 28.7 0%–100%
Time to first AF episode (days) 7.3 ± 7.6 1–28
Mean heart rate during AF
episodes (beats/minute)
105 ± 26.9 60–160
Table 1 Characteristics of the total study population, AF patients and non-AF patients
Total population AF Non-AF P-value
detection rate (%) 95% CI
Total, n 928 35 3.8% (2.7–5.2) 893
Men, n (%) 462 (49.8%) 21 (60.0%) 4.6% (3.0–6.8) 441 (49.4%) 0.218
Women, n (%) 466 (50.2%) 14 (40.0%) 3.0% (1.8–5.0) 452 (50.6%)
Age < 65 years, n (%) 242 (26.1%) 7 (20.0%) 2.9% (1. 4–5.8) 235 (26.3%) 0.404
Age ≥65 years, n (%) 686 (73.9%) 28 (80.0%) 4.1% (2.8–5.8) 658 (73.7%)
CHADS2 = 1, n (%) 415 (44.7%) 13 (37.1%) 3.1% (1.7–5.1) 403 (45.1%) 0.351
CHADS2 ≥ 2, n (%) 513 (55.3%) 22 (62.9%) 4.3% (2.8–6.3) 490 (54.9%)
CHF, n (%) 34 (3.7%) 1 (2.9%) 2.9% (0.7–14.9) 33 (3.7%) 0.796
HT, n (%) 838 (90.3%) 31 (88.6%) 3.7% (2.6–5.2) 807 (90.4%) 0.724
Age ≥75 y, n (%) 326 (35.0%) 13 (37.1%) 4.0% (2.6–7.1) 313 (35.1%) 0.799
DM, n (%) 293 (31.6%) 12 (34.3%) 4.1% (2.4–7.0) 281 (31.5%) 0.725
ES, n (%) 80 (8.6%) 4 (11.4%) 5.0% (2.0–12.2) 76 (8.5%) 0.546
IHD*, n (%) 184 (19.8%) 5 (14.3%) 2.7% (1.2–6.2) 179 (20.0%) 0.402
Total population AF Non-AF
Mean SD Range Mean SD Range Mean SD Range P-value
Number of ECG registrations, n 55.4 ± 11.2 1–125 50.3 ± 22.1 1–96 55.6 ± 10.5 20–125 0.442
Age, y 69.8 ± 9.4 33–89 70.7 ± 7.7 53–85 69.8 ± 9.4 33–89 0.679
Median Range Median Range Median Range
CHADS2 total 2 1–5 2 1–4 2 1–5 0.451
CHF Congestive heart failure, HT Hypertension, DM Diabetes mellitus, ES Earlier stroke/TIA, IHD Ischemic heart disease (* not included in CHADS2). P-values
compare AF with non-AF patients. Participants can have more than one co-morbidity.
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of AF in an out-of-hospital population. A British multi-
centre randomized controlled trial using systematic and/
or opportunistic screening with pulse control and 12-lead
ECG to detect AF among people over 65 years found
incidences of less than 2% newly diagnosed AF for all
methods (even when including patients detected outside
the screening programme), within a year of screening
[21,22]. Another study screening of a general practice
population using pulse assessment found about 1% previ-
ously unknown AF [23]. Studies of post-stroke patients es-
timated a prevalence of 3.8–8.4% previously undiagnosed
AF using 24-hour Holter and Event loop recorder ECG
[17-19]. A recent Swedish study shows that intermittent
handheld ECG recording compared with 24-hour Holter
ECG substantially improves the detection of silent parox-
ysmal atrial fibrillation (AF) in post-stroke patients [20].
Continuous monitoring during a follow-up of 1.1 ±
0.7 years with an implanted device resulted in detection of
30% previously unknown AF, in a population of patients
with risk factors for stroke, who had recently received a
pacemaker, implantable cardioverter defibrillator or car-
diac resynchronization therapy device [26]. Using such
implantable devices for screening in large out-of-hospital
populations is at present not suitable for economic rea-
sons. Other devices, e.g. patch-based appliances with the
Figure 4 Time from inclusion until AF detection.
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however become an alternative for screening in large
out-of-hospital populations [27].
The study design does not allow for any assessment of
how representative the population is. The detection rate
of AF, mean age and mean CHADS2 were comparable at
all ten centres and this together with the size of the
study population, consecutive inclusion, a very high par-
ticipation rate and low drop-out increases the likeliness
of representativeness.
Device and method
The novelty in this study compared to other studies
screening for AF is both the device itself and the screen-
ing method of prolonged intermittent recording for four
weeks, both regularly and when having symptoms.
Handheld ECG in combination with the chosen screen-
ing method has advantages compared to other, traditional
screening instruments. The device is small and involves al-
most no limitation to the mobility of the patients. Regis-
trations are easy to perform and compliance is high, as
supported by the results of the present study where 95%
of all included patients had sufficient technical recordings.
The ECG recording can immediately be transmitted to a
website and assessed directly. Since there was no compari-
son group, cost-effectiveness cannot be addressed. The
cost per screened patient using this method of screening
is less than €100.
Future screening: high compliance; shorter screening
period?
The high compliance rate using this method indicates that
it is feasible as a screening instrument for AF. More than
80% of AF diagnoses with handheld ECG were found
within 14 days, suggesting that the registration period can
be shortened without losing too much information. A
major screening study has been launched in which 25 000
Swedes aged 75 and 76 years are randomized either toparticipate in a 14-day screening programme using 30-
second handheld intermittent ECG recording to detect
asymptomatic AF, or to act as control group [28].
Detection of patients with conduction system disease
Six Holter investigations were done because of suspected
brady-arrhythmias and five patients received a pace-
maker because of diagnosis of AV block II-III or sinus
arrest. All five patients were symptomatic, reporting
dizziness and syncope but had not contacted healthcare
previously. They were on average slightly older, had
higher CHADS2 scores and significantly more ischemic
heart disease (P = 0.024) compared to patients not re-
ceiving a pacemaker.
Limitations
One quarter of the new AF cases were identified at the
first registration, so they would have been detected
with routine care involving a pulse check and/or ECG.
The additional value of the handheld ECG with inter-
mittent registrations is therefore in the detection of the
remaining patients.
Seven out of 35 AF patients were confirmed only after
an additional 24-hour Holter ECG. This makes it more
difficult to say how many patients would have been
found after a shorter screening of two weeks (decisions
about doing an additional Holter were only made after
the whole four-week period). Nevertheless only 24
Holter recordings were needed to find seven more AF
cases, which makes this kind of intermittent screening
still very efficient.
We used registrations of only 10 seconds due to the
limited capacity of the handheld device; we do not know
at present whether 30-second registrations of AF, as
used in guidelines, are more relevant. The AF definition
used by the European Society of Cardiology in its Guide-
lines from 2010 – ‘Any arrhythmia that has the ECG
characteristics of AF and lasts sufficiently long for a 12-
Hendrikx et al. BMC Cardiovascular Disorders 2013, 13:41 Page 7 of 8
http://www.biomedcentral.com/1471-2261/13/41lead ECG to be recorded, or at least 30 s on a rhythm
strip, should be considered as AF’ – is not empirical, but
based on consensus [9]. Standard 12-lead ECG is a 10-
second strip and diagnosis of AF based on a 10-second
12-lead resting ECG is used in other recent studies [6].
Providing lifelong anticoagulation to someone with a
single 10-second episode of AF is definitely a leap too
far at this stage. The patients in this study, however, had
AF on more than 30% of their registrations on average
(almost three minutes in a total registration time of only
eight and a half minutes). Only AF registrations that
lasted the full 10 seconds were counted as AF. How long
these episodes lasted in reality is impossible to say. Two
patients had a single 10-second episode of AF, which
could not be reproduced during follow-up. It is therefore
important in future screening projects that patients
complete the screening period even if AF is diagnosed
and further confirmatory testing will be required in
many patients.
A disadvantage of the handheld ECG device is that
only lead I is recorded, which sometimes makes it
difficult to distinguish (1:1 and 2:1 blocked) atrial flutter
from a regular supraventricular re-entry tachycardia
such as AV-nodal re-entry tachycardia, which might
have resulted in underdetection of atrial flutter [25]. At
the same time, we cannot exclude the possibility of
some cases with short runs of atrial tachycardia being
mislabelled as AF because of the short 10-second re-
cording time [25]. Ideally, this study should have been
performed along with a more continuous monitoring
device to help assess the accuracy of the outcomes.Conclusions
Opportunistic screening with intermittent handheld ECG
registration over four weeks showed a detection rate of
3.8% of previously undiagnosed AF, in a population (n =
928) of relatively healthy and relatively young, out-of-hos-
pital patients having at least one additional risk factor for
stroke. This study shows very high compliance suggesting
that opportunistic screening using this method could be a
feasible technique for detection of AF.
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